Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 50 for:    "Prosthetic Joint Infection"

Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection (PROOF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03260010
Recruitment Status : Recruiting
First Posted : August 24, 2017
Last Update Posted : April 19, 2018
Sponsor:
Collaborator:
Charite University, Berlin, Germany
Information provided by (Responsible Party):
Pro-Implant Foundation

Tracking Information
First Submitted Date  ICMJE August 15, 2017
First Posted Date  ICMJE August 24, 2017
Last Update Posted Date April 19, 2018
Actual Study Start Date  ICMJE January 15, 2018
Estimated Primary Completion Date April 15, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 21, 2017)
Infection cure rate [ Time Frame: 1 year ]
Proportion of patients free of PJI relapse (i.e. infection cure rate) within 1 year after inclusion. Relapse is defined as new PJI diagnosis more than 4 weeks after the last surgical intervention of the initial 12 week treatment period.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03260010 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 21, 2017)
  • Infection cure rate [ Time Frame: 2 years ]
    Proportion of patients free of Prosthetic Joint-Infection relapse (infection cure rate) within 2 years after inclusion
  • Proportion of patients with revision [ Time Frame: 1 year ]
    Proportion of patients with revision (surgical intervention with or without prosthesis removal >4 weeks after last surgical intervention of the initial 12 week treatment period)
  • Proportion of patients with revision due to hematogenous versus non-hematogenous infection [ Time Frame: 1 year ]
    Proportion of patients with revision due to hematogenous (acute onset with duration of symptoms <3 weeks and onset of symptoms is >3 months after last surgery) versus non-hematogenous infection
  • Proportion of patients with unscheduled early revisions [ Time Frame: 1 year ]
    Proportion of patients with unscheduled early revisions (<4 weeks after last scheduled surgical intervention - deep (= bone/joint) revision versus superficial (= skin-soft tissue) revision)
  • Proportion of patients with aseptic revision [ Time Frame: 1 year ]
    Proportion of patients with aseptic revision
  • Proportion of patients with implant failure [ Time Frame: 1 year ]
    Proportion of patients with implant failure (any functionally affected or pain producing implant, clinically relevant abnormal laboratory test result indicating PJI, or presence of radiological signs of loosening, according to the investigator (Yes/No))
  • Proportion of patients with treatment failure [ Time Frame: 1 year ]
    Proportion of patients with treatment failure (insufficient primary therapy or PJI relapse)
  • Proportion of patients with initially sufficient versus insufficient primary therapy [ Time Frame: 1 year ]
    Proportion of patients with initially sufficient versus insufficient primary therapy (defined by the judgement of the investigator, based on combined clinical, laboratory, microbiological and radiological criteria, e.g. clear reduction of wound secretion)
  • Specific functional joint scores [ Time Frame: 1 year ]
    Development and changes vs baseline of specific functional joint scores
  • EQ5D5L [ Time Frame: 1 year ]
    EQ5D5L (in particular for 1 year follow up)
  • Safety and tolerability of fosfomycin (frequency of adverse events) [ Time Frame: 1 year ]
    Safety and tolerability of fosfomycin will be evaluated by measuring the frequency of adverse events, including potential side effects
  • Pharmacokinetic profile of fosfomycin in plasma [ Time Frame: 1 year ]
    Pharmacokinetic profile of fosfomycin in plasma (steady state after a single application per patient): Cmax
  • Pharmacokinetic profile of fosfomycin in plasma [ Time Frame: 1 year ]
    Pharmacokinetic profile of fosfomycin in plasma (steady state after a single application per patient): Tmax
  • Pharmacokinetic profile of fosfomycin in plasma [ Time Frame: 1 year ]
    Pharmacokinetic profile of fosfomycin in plasma (steady state after a single application per patient): Cmin 8 h
  • Pharmacokinetic profile of fosfomycin in plasma [ Time Frame: 1 year ]
    Pharmacokinetic profile of fosfomycin in plasma (steady state after a single application per patient): t1/2
  • Pharmacokinetic profile of fosfomycin in plasma [ Time Frame: 1 year ]
    Pharmacokinetic profile of fosfomycin in plasma (steady state after a single application per patient): AUC0-8
  • Pharmacokinetic profile of fosfomycin in plasma [ Time Frame: 1 year ]
    Pharmacokinetic profile of fosfomycin in plasma (steady state after a single application per patient): extrapolated AUC0-24
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection
Official Title  ICMJE Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection (PJI) Caused by Staphylococci, Streptococci, Enterococci and Gram-negative Bacilli, Including Mixed Infections and Culture Negative PJI's ("PROOF-Study")
Brief Summary The PROOF Study is an open prospective interventional non-randomized study which aim is to determine the outcome / effect and safety of fosfomycin in patients with hip, knee or shoulder PJI.
Detailed Description To confirm a non-inferior effect and the safety of the investigated antimicrobial fosfomycin regimen in PJI of the hip, knee or shoulder against an assumed 80% effect (PJI-free proportion within one year for standard antibiotics aside fosfomycin), following a standardized surgical therapy involving retention, one-stage exchange or two-stage exchange (with short or long interval).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Intervention Model: Single Group Assignment
Intervention Model Description:
In this open prospective interventional clinical study patients with hip, knee or shoulder PJI (as defined below) caused by fosfomycin-susceptible staphylococci, streptococci, enterococci or gram-negative bacilli will be included. After inclusion and PJI-surgery, intravenous fosfomycin will be given 5 g every 8 hours for 1, 2, 3-or -4 weeks according to the pathogen and surgery procedure and generally as a part of the antibiotic combination therapy of the treatment algorithm. This Treatment is followed by oral antibiotics for a total of 3 months.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Prosthetic Joint Infection
Intervention  ICMJE Drug: Fosfomycin
Infectofos 5 g
Study Arms  ICMJE Experimental: Fosfomycin Arm
Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
Intervention: Drug: Fosfomycin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 21, 2017)
224
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 15, 2021
Estimated Primary Completion Date April 15, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Informed consent has been obtained (prior to planned surgical PJI treatment);
  2. Subject is ≥18 years of age;
  3. Subject has either a culture negative or a culture positive PJI of the hip, knee or shoulder prosthesis: (i) visible purulence of a preoperative aspirate or intraoperative periprosthetic tissue (as determined by the surgeon),or (ii) presence of a sinus tract communicating with the prosthesis, or (iii) acute inflammation in intraoperative permanent tissue sections by histopathology (as determined by the pathologist), or (iv) microbial growth in preoperative joint aspirate, intraoperative periprosthetic tissue or sonication fluid of the removed implant (>50 CFU/ml sonication fluid), or (v) synovial fluid with >2000 leukocytes/μl or >70% granulocytes; or reasonable evidence for a suspected PJI (based on clinical, laboratory, and radiological criteria) to undergo joint surgery to proof the PJI diagnosis (according to standard of care, Zimmerli W et al. NEJM 2004);
  4. For culture positive PJI's at least one of the following isolates:

    staphylococci (fosfomycin MHK ≤ 32 mg/ml), streptococci (MHK ≤ 128 mg/ml), enterococci (MHK ≤ 128 mg/ml), fosfomycin susceptible gram-negative bacilli, including also mixed infections with other pathogens (fosfomycin susceptible or not);

  5. Subject is planned to/will undergo appropriate surgical procedure following the state of the art PJI treatment algorithm, which includes either debridement & retention of the prosthesis or exchange of the prosthesis. The exchange includes a one-stage exchange, two-stage prosthesis exchange with a short interval (2- 3 weeks) or long interval (6-8 weeks), according to the treatment algorithm;
  6. Subject is willing to participate in the study, follow protocol study treatment regimen, and comply with all planned follow-up assessments.

Exclusion Criteria:

  1. Allergy or intolerance (or other contraindication) to fosfomycin;
  2. Isolation of fungi (molds or yeasts) or mycobacteria;
  3. Isolation of one of the following pathogens: staphylococci fosfomycin MHK > 32 mg/ml, streptococci MHK > 128 mg/ml, enterococci MHK > 128 mg/ml , fosfomycin resistant gramnegative bacilli;
  4. Severely compromised bone/soft tissue pre or during surgery (if during surgery: exclusion/withdrawal before IMP application);
  5. Pregnancy, and/or woman wishing to become pregnant;
  6. Breast-feeding;
  7. Women of childbearing potential without at least one of the following contraception methods: correctly placed cooper containing or progestin-containing intrauterine device (IUD); female condom used WITH a spermicide (i.e. foam gel, film, cream, or suppository); bilateral tubal ligation/bilateral salpingectomy or bilateral tubal occlusive procedure (at least till the end of the ambulatory treatment phase);
  8. Subject has been previously enrolled in this study or was enrolled in another interventional medicinal product or medical device study in the last 30 days;
  9. Subject had prior exposure to fosfomycin within the past 4 weeks;
  10. Inability to read and understand the participant's information;
  11. Subjects institutionalized by warrant or court order;
  12. Employees of the sponsor or an involved CRO;
  13. In pre surgery culture negative patients: All isolates unsusceptible to fosfomycin after surgery (exclusion / early withdrawal after surgery);
  14. Suspected PJI not proven after surgery (exclusion / early withdrawal after surgery).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Alessandra Bardelli, MSCPH, MScAC (+49) 030 450 652416 alessandra-catalina.bardelli@charite.de
Contact: Andrej Trampuz, PD Dr (+49) 030 450 615073 andrej.trampuz@charite.de
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03260010
Other Study ID Numbers  ICMJE PROOF
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Pro-Implant Foundation
Study Sponsor  ICMJE Pro-Implant Foundation
Collaborators  ICMJE Charite University, Berlin, Germany
Investigators  ICMJE
Principal Investigator: Andrej Trampuz, PD Dr. Charité - Univeristätsmedizin
PRS Account Pro-Implant Foundation
Verification Date August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP